David C. Montefiori

This study shows that sequential vaccination can mature VRC01-class B cells into antibodies that neutralize a broad range of HIV-1 viruses.

The paper investigates whether genetically diverse B-cell receptor responses in simian-HIV infected macaques converge functionally, finding that functional convergence does not require genetic convergence.

The paper shows that boosting at the same site as the initial immunization preferentially engages bnAb lineage precursors in secondary germinal centers, while contralateral boosting recruits naive and non-specific memory B cells.

This paper develops updated HIV-1 pseudovirus panels to better detect and assess B cell lineages with potential to produce broadly neutralizing antibodies against contemporary HIV-1 variants.

The paper analyzes HIV breakthrough virus populations in antibody-mediated prevention trials, finding high rates of multilineage infections and recombination under VRC01 treatment.

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.

This study compares neutralization susceptibility of clade C HIV viruses from breastmilk to those from sexual transmission, finding breastmilk viruses more resistant to certain broadly neutralizing antibodies.

This study identifies VRC01-mediated viral escape mutations in HIV-infected participants from antibody-mediated prevention trials, showing that VRC01 can select for escape variants with cross-resistance to other CD4bs bnAbs.

This study shows that targeting the conserved HIV fusion peptide with modified Env immunogens in rhesus macaques can focus immune responses on neutralizing epitopes.

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

This study compares bnAb precursor responses in infant and juvenile rhesus macaques after germline-targeting HIV Env immunization, finding higher rates in infants.

This study engineers an HIV broadly neutralizing antibody to improve its potency, antiviral activity, and manufacturability while maintaining safety and efficacy.

This study shows that higher valency immunogens promote the maturation of VRC01-class antibodies with broader neutralizing activity in animals.

This study shows that a multi-dose immunization with germline-targeting SOSIP vaccines induces precursor broadly neutralizing antibodies in infant macaques, similar to adult responses.

The paper determines cryo-EM structures of SARS-CoV-2 XBB lineage spike proteins, revealing structural changes that enhance immune evasion and receptor binding.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

This paper evaluates multivalent HIV-1 Env immunization strategies in guinea pigs and adapts LIBRA-seq for antibody discovery, finding optimal cocktail sizes and identifying public clonotypes.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.

The paper identifies infant-transmitted HIV-1 variants that are neutralization-resistant to maternal plasma but sensitive to broadly neutralizing antibodies, suggesting maternal antibody responses select for these resistant variants during peripartum transmission.